Evolus (EOLS) Cash & Current Investments (2018 - 2026)
Evolus (EOLS) posted Cash & Current Investments of $49.8 million for Q1 2026, down 7.49% on a QoQ basis from $53.8 million in Q4 2025, and down 26.66% year-over-year from $67.9 million in Q1 2025.
Evolus (EOLS) Cash & Current Investments (2018 - 2026) Analysis & Trends
Evolus' Cash & Current Investments history runs 9 years deep, the most recent figure standing at $49.8 million for Q1 2026.
- Quarterly Cash & Current Investments fell 26.66% year-over-year to $49.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.8 million (down 26.66% YoY) and the FY2025 annual result came in at $53.8 million, down 38.1% from the prior year.
- Cash & Current Investments was $49.8 million for Q1 2026 at Evolus, down from $53.8 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $106.7 million in Q1 2022 and bottomed at $31.5 million in Q1 2023.
- A 5-year average of $66.2 million and a median of $62.8 million in 2023 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 381.13% — and 2023, when it tumbled 70.5%.
- Evolus' Cash & Current Investments stood at $53.9 million in 2022, then grew by 16.53% to $62.8 million in 2023, then jumped by 38.37% to $87.0 million in 2024, then slumped by 38.1% to $53.8 million in 2025, then slipped by 7.49% to $49.8 million in 2026.
- Business Quant data shows EOLS's Cash & Current Investments at $49.8 million in Q1 2026, $53.8 million in Q4 2025, and $43.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 90.13 Bn | 88.27 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 35.98 Bn | 32.24 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 23.08 Bn | 20.93 Bn | 648.10 Mn | 2.15 Bn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.38 Bn | 18.57 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.48 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Evolus | 399.92 Mn | 350.13 Mn | 48.90 Mn | 49.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.79 Mn |
| Dec 31, 2025 | 53.83 Mn |
| Sep 30, 2025 | 43.52 Mn |
| Jun 30, 2025 | 61.74 Mn |
| Mar 31, 2025 | 67.89 Mn |
| Dec 31, 2024 | 86.95 Mn |
| Sep 30, 2024 | 85.04 Mn |
| Jun 30, 2024 | 93.67 Mn |
| Mar 31, 2024 | 96.96 Mn |
| Dec 31, 2023 | 62.84 Mn |
| Sep 30, 2023 | 38.69 Mn |
| Jun 30, 2023 | 41.71 Mn |
| Mar 31, 2023 | 31.46 Mn |
| Dec 31, 2022 | 53.92 Mn |
| Sep 30, 2022 | 65.57 Mn |
| Jun 30, 2022 | 84.48 Mn |
| Mar 31, 2022 | 106.67 Mn |
| Dec 31, 2021 | 146.26 Mn |
| Sep 30, 2021 | 107.80 Mn |
| Jun 30, 2021 | 131.74 Mn |